Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
For best results when printing this announcement, please click on link below: Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in Atlanta, Georgia from October 17 through October 19. The AABB Annual Meeting attracts healthcare professionals, scientists, and other experts from around the globe involved in transfusion medicine and biotherapies. “We are pleased to highlight IFC at the 2026 AABB Annual Meeting, including an industry workshop focused on real-world experiences,” said Vivek Jayaraman, Cerus’ president and chief executive officer. “The meeting provides an important opportunity to share scientific data and engage with the transfusion medicine community.” The following is a select list of Cerus-related presentations and abstracts. All presentation times are listed in Eastern Time (ET). Cerus-Sponsored Industry Workshop at AABB Sunday, Oc
For best results when printing this announcement, please click on link below: Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in Atlanta, Georgia from October 17 through October 19.
The AABB Annual Meeting attracts healthcare professionals, scientists, and other experts from around the globe involved in transfusion medicine and biotherapies. “We are pleased to highlight IFC at the 2026 AABB Annual Meeting, including an industry workshop focused on real-world experiences,” said Vivek Jayaraman, Cerus’ president and chief executive officer. ” The following is a select list of Cerus-related presentations and abstracts. All presentation times are listed in Eastern Time (ET).
m. m. ET. m.
m. Bacterial Contamination of Platelets with Large Volume Delayed Sample (LVDS) Culture or Amotosalen/UVA Pathogen Reduction (PR) (Speaker: R. m. m.
Prospective Comparison of Pathogen-Reduced and Conventional Cryoprecipitate in Liver Transplantation (Speaker: S. S. (Poster # P-TS-5) Two decades of amotosalen/UVA platelet and plasma hemovigilance in Europe (Poster # P-TS-97) Operational Experience With Amotosalen/UVA Pathogen Reduction for On-Demand Apheresis Platelets in Morelos, Mexico (Poster # P-IV-5) The full program of Cerus-related abstracts can be found at the following Cerus representatives will be in the exhibition area at booth #915. Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT Fibrinogen Complex, or IFC.
About Cerus Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components.
, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. S. For more information about Cerus, visit and follow us on LinkedIn. Cerus, INTERCEPT, and the Cerus logo are trademarks of Cerus Corporation.
com 925-288-6128